ANXA9 ELISA kit
- Known as:
- ANXA9 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- DL-ANXA9-Hu
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- WDSTD
- Gene target:
- ANXA9 ELISA kit
Related genes to: ANXA9 ELISA kit
- Gene:
- ANXA9 NIH gene
- Name:
- annexin A9
- Previous symbol:
- ANX31
- Synonyms:
- -
- Chromosome:
- 1q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-12-11
- Date modifiied:
- 2016-10-05
Related products to: ANXA9 ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: ANXA9 ELISA kit
- The connection between immunity and Parkinson’s disease (PD) is well-established. Myeloid immune responses influence the microenvironment of the central nervous system (CNS), which can be modulated by sargramostim, a recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). Previous studies have demonstrated sargramostim’s neuroprotective effects, which are linked to its safety and tolerability, as well as its ability to regulate innate immunity. Changes in myeloid biomarkers correlate with clinical responses. PD symptoms were assessed using the Unified PD Rating Scale (UPDRS). Ten subjects received sargramostim through subcutaneous injections of 3 µg/kg, administered five days every week. Myeloid biomarkers were measured before treatment and at six and twelve months of treatment. Protein expression by Western blotting and gene expression by transcriptomic analysis was correlated with UPDRS III scores. Recognizing the exploratory nature of this study, patient responses were classified into potent, moderate, or no change groups based on UPDRS III score reductions of 9–13, 5–7, or none, respectively. Biomarkers from all 10 patients identified FOXP3 as a “potential” signature biomarker. The potent responders showed biomarkers linked to autophagy, inflammatory, and antioxidant proteins, including ATG7, HMOX1, RELA, and TLR8. Moderate responders displayed biomarkers associated with RELA and LRRK2. Transcriptomic analysis revealed over 2000 differentially expressed anti-inflammatory, calcium-binding, and epigenetic genes. Among these, genes such as ANXA9, CALM3, CY7B1, HDAC4, HMGB2, NR2F6, PDIA3, REST, SACS and SOX4 were identified as potential predictors of changes in UPDRS III scores. Baseline levels of ATG7, CARD9, and SACS may serve as initial biomarkers to identify subjects likely to respond to sargramostim. Female patients exhibited unique UPDRS III scores in response to sargramostim treatment. Novel cell-based biomarker signatures were identified that may predict responses to sargramostim treatment in this hypothesis-generating study. We acknowledge the inherent study limitations by limited patient numbers. This was reflected in the comparisons offered for the patient sub-groups in the year-long trial.Trial Registration The trial is registered on ClinicalTrials.gov under identifier NCT03790670, dated 01.30.2019. - Source: PubMed
Publication date: 2026/04/01
Sil SusmitaDu XiaoqingAkter SamiaKumar MohitOludipe Davina BSaha ArnabHu GuokuOstlund Katie RHaynatzki Gleb RSantamaria PamelaMosley R LeeGendelman Howard E - Colorectal cancer (CRC) represents a major public health challenge [...]. - Source: PubMed
Publication date: 2025/11/18
Zeng Shi-JieHe KeShi Zhi - Ulcerative colitis (UC) is a life-threatening heterogeneous condition characterized by inflammation of the colon. Endoplasmic reticulum aminopeptidase 1 (ERAP1) is essential for antigen processing and immune regulation, however, its specific role in UC pathogenesis and therapeutic response remains unclear. This study aimed to investigate the role of ERAP1 in the response to sulfasalazine, a standard treatment for UC, using an ERAP1-heterozygous (ERAP1) mouse model susceptible to colitis. - Source: PubMed
Publication date: 2025/09/05
Riaz BushraRyu Hye-MyungIslam S M ShamsulBabita RaharSeong Je KyungLee HoLee Eunjoo HSohn Seonghyang - Colorectal cancer (CRC) is a major global health challenge, creating an urgent need to find new biomarkers that improve early detection and treatment success. While studies suggest that ANXA9 contributes to cancer development, its expression in CRC and its links to prognosis, immune evasion, and resistance are poorly understood. - Source: PubMed
Publication date: 2025/09/01
Hong MingyangDong QianZhu HuimingHuang Xu - This study intended to figure out the effects of fixed effects and genes such as beta-lactoglobulin (β-LG), prolactin (PRL), annexin A9 (ANXA9), and acetyl-CoA acyltransferase 2 (ACAA2) on the structure of fatty milk acids in Awassi ewes, as well as any potential genotype-genotype interactions. - Source: PubMed
Publication date: 2025/03/25
Jawasreh Khaleel IKhrais DanaAlu'datt MuhammadHaddad Nizar JAwabdeh SamiAlMadani Mohammad IsamBrake MohamadAl-Araishi Mohamad AhmadSadder MontherAl-Amareen Ahmad